A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers	Solid Tumors	Active, not recruiting	Phase 1	2026-08-26		NCT03448042

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Genentech, Inc.	221

26 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asan Medical Center	Seoul	South Korea	338
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda	Milan	Italy	2
Centre Léon Bérard	Lyon	France	2
China Medical University Hospital	Taichung	Taiwan	88
Churchill Hospital	Oxford	United Kingdom	1
EDOG - Institut Bergonie - PPDS	Bordeaux	France	3
Grand Hopital de Charleroi asbl	Charleroi	Belgium	3
Gustave Roussy	Villejuif	France	10
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis	Amsterdam	Netherlands	3
Hospital Clinico Universitario de Valencia	Valencia	Spain	109
Hospital Universitari Vall d'Hebron	Barcelona	Spain	200
Hospital Universitario Quironsalud Madrid	Pozuelo de Alarcón	Spain	20
Institut Claudius Regaud	Toulouse	France	40
MD Anderson Cancer Center	Houston	United States	589
Memorial Sloan Kettering Cancer Center	New York	United States	5
National Cancer Centre	Singapore	Singapore	13
National Taiwan University Hospital	Taipei	Taiwan	32
Peter MacCallum Cancer Centre	Melbourne	Australia	149
Princess Margaret Hospital	Toronto	Canada	21
Rigshospitalet-Blegdamsvej 9	Copenhagen	Denmark	2
Scri Oncology Partners	Nashville	United States	156
Seoul National University Hospital	Seoul	South Korea	18
START MADRID_Hospital Universiario Fundacion Jimenez Diaz	Madrid	Spain	2
START MADRID_Hospital Universitario HM Sanchinarro - CIOCC - EDOS	Madrid	Spain	1
Washington University	Saint Louis	United States	2

Clinical trials